North American Neuromodulation Market

Market Introduction

Neuromodulation is the process of regulating the activity of nerves by controlling the physiological level of neurotransmitters. These modifications are brought about with the help of various devices or by drug infusion. These devices contain small electrodes that are placed on the spinal cord, brain or the peripheral nerves. Neurological disorders such as, cerebrovascular diseases, Alzheimer disease and Parkinson's disease affect the neurological functioning of the body and hence can be treated with the help of neuromodulation.

Market Overview and Dynamics

The North America Neuromodulationmarketis projectedto reach US$ 6,612.00 millionby 2027 from US$ 3,029.72million in 2019; it is estimated to grow with a CAGR of 10.6% from 2020 to 2027.The growth of the North America neuromodulationmarket is attributed to the increasing incidence of neurological disorders, growing developments in neuromodulation technology. However, high cost of neuromodulation devicesthe growth of market in this region. leading to restraining the growth of the market.

Key Market Segments

Based on technology, the North America neuromodulationmarket is segmented into external (non-invasive) neuromodulation and internal neuromodulation. In 2019, the internal neuromodulationsegment held a larger share of the market. External (non-invasive) neuromodulationis expected to grow at a faster rate during the forecast period.

Major Sources and Companies Listed

A few major primary and secondary sources referred towhile preparing the North Americaneuromodulationmarketreport are World Health Organization, Ministry of Health and Prevention, and Ministry of Health and Family Welfare.

Abbott, Boston Scientific Corporation, Medtronic, NeuroPace, Inc., NeuroSigma, Inc., NEVRO CORP, Synapse Biomedical Inc., Soterix Medical Inc, Integer Holdings Corporation, and Magstim.

Reasons to buy the report

• To understand the North America neuromodulationmarketlandscape and identifymarket segments that are most likely to guarantee a strong return
• To stay ahead incomprehending the ever-changing competitive landscape of theNorth Americaneuromodulationmarket
• To efficiently plan M&A and partnership dealsin the North Americaneuromodulationmarketby identifying market segments with the most promising probable sales
• To help takeknowledgeable business decisions from perceptive and comprehensive analysis of market performance of various segmentsinthe North Americaneuromodulationmarket
• To obtain market revenue forecast from 2019 to 2027 in various segmentsofthe North Americaneuromodulationmarket

NORTH AMRICA NEUROMODULATION MARKETSEGMENTATION

By Technology

·         External (Non-Invasive) Neuromodulation

o    Respiratory Electrical Stimulation

o    Transcutaneous Electrical Nerve Stimulation

o    Transcranial Magnetic Stimulation

·         Internal Neuromodulation

o    Deep Brain Stimulation

o    Sacral Nerve Stimulation

o    Gastric Electrical Stimulation

o    Spinal Cord Stimulation

o    Vagus Nerve Stimulation

By Application

·         Chronic Pain Management

·         Failed Back Syndrome

·         Epilepsy

·         Tremor

·         Incontinence

·         Depression

·         Dystonia

·         Gastroparesis

·         Parkinson’s Disease

·         Obsessive-Compulsive Disorder

·         Migraine

By End User

·         Hospitals

·         Clinics

·         Home Healthcare

By Country

·         US

·         Canada

·         Mexico

Company Profiles

• Abbott
• Boston Scientific Corporation
• Medtronic
• NeuroPace, Inc.
• NeuroSigma, Inc.
• NEVRO CORP.
• Synapse Biomedical Inc.
• Soterix Medical Inc
• Integer Holdings Corporation

• Magstim

North American Neuromodulation Market Strategic Insights

North American Neuromodulation Market Segmentation Analysis

North American Neuromodulation Market Report Highlights

North American Neuromodulation Report Scope

North American Neuromodulation Market Country and Regional Insights